Expression B-Premise
of I-Premise
somatostatin I-Premise
receptors I-Premise
is I-Premise
found I-Premise
in I-Premise
HCCs I-Premise
, I-Premise
but O
the B-Claim
efficacy I-Claim
of I-Claim
the I-Claim
somatostatin I-Claim
analogue I-Claim
octreotide I-Claim
remains I-Claim
controversial I-Claim
. I-Claim

Patient B-Claim
preference I-Claim
, I-Claim
demographic I-Claim
variables I-Claim
, I-Claim
and I-Claim
medical I-Claim
variables I-Claim
moderated I-Claim
the I-Claim
effects I-Claim
of I-Claim
exercise I-Claim
training I-Claim
in I-Claim
breast I-Claim
cancer I-Claim
patients I-Claim
who I-Claim
were I-Claim
receiving I-Claim
chemotherapy I-Claim
. I-Claim

Replacement B-Claim
of I-Claim
most I-Claim
hospital I-Claim
follow I-Claim
- I-Claim
up I-Claim
visits I-Claim
in I-Claim
the I-Claim
first I-Claim
year I-Claim
after I-Claim
breast I-Claim
cancer I-Claim
treatment I-Claim
by I-Claim
nurse I-Claim
- I-Claim
led I-Claim
telephone I-Claim
follow I-Claim
- I-Claim
up I-Claim
does I-Claim
not I-Claim
impede I-Claim
patient I-Claim
outcomes I-Claim
. I-Claim

We O
assessed O
HRQOL O
at O
baseline O
and O
at O
every O
3 O
months O
during O
treatment O
until O
progression O
using O
the O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
( O
EORTC O
) O
quality O
of O
life O
questionnaire O
core O
- O
30 O
( O
QLQ O
- O
C30 O
) O
and O
the O
EORTC O
brain O
cancer O
module O
( O
EORTC O
BN O
- O
20 O
) O
. O

Tumor B-Premise
response I-Premise
rates I-Premise
were I-Premise
comparable I-Premise
between I-Premise
treatment I-Premise
arms I-Premise
( I-Premise
10 I-Premise
. I-Premise
2 I-Premise
% I-Premise
v I-Premise
8 I-Premise
. I-Premise
2 I-Premise
% I-Premise
) I-Premise
. I-Premise

The O
8 O
- O
week O
programme O
of O
2 O
h O
sessions O
comprised O
of O
thematic O
discussions O
, O
information O
and O
training O
in O
stress O
management O
techniques O
. O

Between O
- O
group O
differences O
were O
tested O
for O
statistical O
significance O
by O
use O
of O
repeated O
- O
measures O
analysis O
, O
and O
reported O
P O
values O
are O
two O
- O
sided O
. O

The B-Premise
- I-Premise
1 I-Premise
and I-Premise
2 I-Premise
- I-Premise
year I-Premise
survival I-Premise
rates I-Premise
were I-Premise
31 I-Premise
and I-Premise
36 I-Premise
% I-Premise
, I-Premise
and I-Premise
10 I-Premise
and I-Premise
11 I-Premise
% I-Premise
respectively I-Premise
. I-Premise

Two O
primary O
end O
points O
were O
examined O
: O
energy O
\/ O
fatigue O
and O
cancer O
- O
specific O
distress O
. O

Patient O
compliance O
with O
respect O
to O
the O
HRQOL O
investigation O
was O
minimum O
74 O
% O
. O

The O
aim O
of O
the O
study O
is O
to O
demonstrate O
that O
intrapatient O
dose O
escalation O
of O
carboplatin O
would O
improve O
the O
outcome O
in O
ovarian O
cancer O
compared O
with O
flat O
dosing O
. O

This B-Claim
trial I-Claim
failed I-Claim
to I-Claim
show I-Claim
a I-Claim
benefit I-Claim
for I-Claim
up I-Claim
- I-Claim
front I-Claim
tandem I-Claim
HDCT I-Claim
compared I-Claim
with I-Claim
standard I-Claim
combination I-Claim
therapy I-Claim
. I-Claim

Without B-Premise
ADT I-Premise
testosterone I-Premise
remained I-Premise
at I-Premise
castrate I-Premise
level I-Premise
for I-Premise
4 I-Premise
months I-Premise
. I-Premise

To O
evaluate O
the O
analgesic O
effect O
, O
safety O
, O
and O
cost O
- O
effectiveness O
of O
controlled O
- O
release O
oxycodone O
( O
CRO O
) O
to O
control O
postoperative O
pain O
in O
patients O
with O
liver O
cancer O
who O
are O
undergoing O
transarterial O
chemoembolization O
. O

Paclitaxel O
was O
administered O
as O
a O
3 O
- O
hour O
intravenous O
infusion O
every O
3 O
weeks O
. O

The B-Claim
use I-Claim
of I-Claim
spherical I-Claim
PVA I-Claim
particles I-Claim
in I-Claim
the I-Claim
manner I-Claim
described I-Claim
herein I-Claim
results I-Claim
in I-Claim
an I-Claim
unacceptably I-Claim
high I-Claim
rate I-Claim
of I-Claim
failed I-Claim
tumor I-Claim
infarction I-Claim
in I-Claim
UAE I-Claim
. I-Claim

Outcomes O
included O
safety O
and O
tolerance O
of O
the O
exercise O
program O
, O
physical O
function O
, O
physical O
activity O
level O
, O
body O
composition O
, O
fatigue O
, O
quality O
of O
life O
and O
psychological O
distress O
. O

We O
investigated O
whether O
monitoring O
and O
protocolized O
treatment O
of O
physical O
symptoms O
alleviates O
fatigue O
. O

There B-Premise
was I-Premise
no I-Premise
difference I-Premise
in I-Premise
overall I-Premise
survival I-Premise
( I-Premise
HR I-Premise
1 I-Premise
. I-Premise
01 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0 I-Premise
. I-Premise
77 I-Premise
to I-Premise
1 I-Premise
. I-Premise
32 I-Premise
) I-Premise
. I-Premise

Worsening O
of O
symptoms O
was O
defined O
as O
an O
increase O
of O
15 O
mm O
or O
more O
from O
baseline O
on O
a O
100 O
mm O
scale O
for O
each O
LCSS O
item O
. O

No B-Premise
pain I-Premise
training I-Premise
patients I-Premise
reported I-Premise
severe I-Premise
pain I-Premise
( I-Premise
> I-Premise
6 I-Premise
on I-Premise
a I-Premise
0 I-Premise
- I-Premise
10 I-Premise
scale I-Premise
) I-Premise
at I-Premise
1 I-Premise
- I-Premise
month I-Premise
outcomes I-Premise
( I-Premise
P I-Premise
= I-Premise
. I-Premise
03 I-Premise
) I-Premise
. I-Premise

The O
2 O
- O
year O
risk O
of O
progression O
for O
baseline O
PSA O
< O
50 O
ng O
\/ O
ml O
, O
50 O
to O
< O
500 O
ng O
\/ O
ml O
, O
and O
≥ O
500 O
ng O
\/ O
ml O
was O
25 O
% O
, O
55 O
% O
, O
and O
76 O
% O
( O
P O
= O
0 O
. O
03 O
) O
in O
CAD O
, O
and O
38 O
% O
, O
64 O
% O
, O
and O
85 O
% O
( O
P O
= O
0 O
. O
006 O
) O
in O
IAD O
, O
respectively O
. O

Of B-Claim
the I-Claim
three I-Claim
regimens I-Claim
tested I-Claim
, I-Claim
the I-Claim
combination I-Claim
of I-Claim
LV5FU2 I-Claim
- I-Claim
irinotecan I-Claim
is I-Claim
the I-Claim
most I-Claim
promising I-Claim
and I-Claim
will I-Claim
be I-Claim
assessed I-Claim
in I-Claim
a I-Claim
phase I-Claim
III I-Claim
trial I-Claim
. I-Claim

The O
EORTC O
24971 O
\/ O
TAX O
323 O
, O
a O
phase O
III O
study O
of O
358 O
patients O
with O
unresectable O
locoregionally O
advanced O
squamous O
cell O
carcinoma O
of O
the O
head O
and O
neck O
, O
showed O
an O
improved O
progression O
- O
free O
and O
overall O
survival O
( O
OS O
) O
with O
less O
toxicity O
when O
docetaxel O
( O
T O
) O
was O
added O
to O
cisplatin O
and O
5 O
- O
fluorouracil O
( O
PF O
) O
for O
induction O
and O
given O
before O
radiotherapy O
( O
RT O
) O
. O

There B-Premise
was I-Premise
no I-Premise
statistically I-Premise
significant I-Premise
effect I-Premise
on I-Premise
the I-Premise
General I-Premise
Quality I-Premise
of I-Premise
Life I-Premise
score I-Premise
( I-Premise
FACT I-Premise
- I-Premise
G I-Premise
) I-Premise
or I-Premise
on I-Premise
any I-Premise
of I-Premise
the I-Premise
individual I-Premise
wellbeing I-Premise
scores I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
Physical I-Premise
( I-Premise
P I-Premise
= I-Premise
. I-Premise
13 I-Premise
) I-Premise
, I-Premise
Emotional I-Premise
( I-Premise
P I-Premise
= I-Premise
. I-Premise
87 I-Premise
) I-Premise
, I-Premise
Social I-Premise
( I-Premise
P I-Premise
= I-Premise
. I-Premise
83 I-Premise
) I-Premise
and I-Premise
Functional I-Premise
( I-Premise
P I-Premise
= I-Premise
. I-Premise
26 I-Premise
) I-Premise
. I-Premise

Alternating O
, O
schedule B-Claim
- B-Claim
specific B-Claim
biochemical I-Claim
modulation I-Claim
of I-Claim
FU I-Claim
is I-Claim
more I-Claim
active I-Claim
than I-Claim
MTX I-Claim
- I-Claim
- I-Claim
> I-Claim
5 I-Claim
- I-Claim
FU I-Claim
as I-Claim
first I-Claim
- I-Claim
line I-Claim
treatment I-Claim
of I-Claim
advanced I-Claim
colorectal I-Claim
cancer I-Claim
. I-Claim

Moreover O
, O
a B-Premise
significant I-Premise
lower I-Premise
serum I-Premise
C I-Premise
- I-Premise
reactive I-Premise
protein I-Premise
level I-Premise
was I-Premise
detected I-Premise
in I-Premise
glutamine I-Premise
- I-Premise
enriched I-Premise
TPN I-Premise
compared I-Premise
with I-Premise
standard I-Premise
TPN I-Premise
( I-Premise
P I-Premise
= I-Premise
0 I-Premise
. I-Premise
013 I-Premise
) I-Premise
. I-Premise

Women O
with O
ovarian O
cancer O
in O
complete O
remission O
after O
first O
- O
line O
platinum O
- O
based O
chemotherapy O
and O
a O
normal O
CA125 O
concentration O
were O
registered O
for O
this O
randomised O
controlled O
trial O
. O

At B-Premise
6 I-Premise
months I-Premise
and I-Premise
2 I-Premise
years I-Premise
, I-Premise
using I-Premise
non I-Premise
- I-Premise
responder I-Premise
analyses I-Premise
, I-Premise
ACR I-Premise
responses I-Premise
in I-Premise
abatacept I-Premise
- I-Premise
treated I-Premise
patients I-Premise
were I-Premise
: I-Premise
ACR I-Premise
20 I-Premise
, I-Premise
59 I-Premise
. I-Premise
4 I-Premise
% I-Premise
and I-Premise
56 I-Premise
. I-Premise
2 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
ACR I-Premise
50 I-Premise
, I-Premise
23 I-Premise
. I-Premise
5 I-Premise
% I-Premise
and I-Premise
33 I-Premise
. I-Premise
2 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
ACR I-Premise
70 I-Premise
, I-Premise
11 I-Premise
. I-Premise
5 I-Premise
% I-Premise
and I-Premise
16 I-Premise
. I-Premise
1 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
HAQ I-Premise
- I-Premise
DI I-Premise
responses I-Premise
were I-Premise
54 I-Premise
. I-Premise
4 I-Premise
% I-Premise
and I-Premise
47 I-Premise
. I-Premise
9 I-Premise
% I-Premise
. I-Premise

Palliation O
was O
defined O
as O
an O
improvement O
of O
one O
point O
or O
more O
in O
the O
categorical O
scale O
. O

The B-Claim
addition I-Claim
of I-Claim
gemcitabine I-Claim
to I-Claim
PB I-Claim
was I-Claim
not I-Claim
associated I-Claim
with I-Claim
a I-Claim
statistically I-Claim
significant I-Claim
improvement I-Claim
in I-Claim
ORR I-Claim
. I-Claim

The B-Premise
most I-Premise
frequent I-Premise
toxic I-Premise
effects I-Premise
were I-Premise
grade I-Premise
3 I-Premise
\/ I-Premise
4 I-Premise
diarrhea I-Premise
( I-Premise
arm I-Premise
A I-Premise
: I-Premise
34 I-Premise
% I-Premise
, I-Premise
B I-Premise
: I-Premise
19 I-Premise
% I-Premise
) I-Premise
, I-Premise
grade I-Premise
3 I-Premise
\/ I-Premise
4 I-Premise
neutropenia I-Premise
( I-Premise
A I-Premise
: I-Premise
5 I-Premise
% I-Premise
, I-Premise
B I-Premise
: I-Premise
19 I-Premise
% I-Premise
) I-Premise
and I-Premise
grade I-Premise
2 I-Premise
\/ I-Premise
3 I-Premise
alopecia I-Premise
( I-Premise
A I-Premise
: I-Premise
26 I-Premise
% I-Premise
, I-Premise
B I-Premise
: I-Premise
65 I-Premise
% I-Premise
) I-Premise
. I-Premise

When B-Premise
wound I-Premise
complication I-Premise
was I-Premise
included I-Premise
in I-Premise
the I-Premise
model I-Premise
, I-Premise
patients I-Premise
with I-Premise
complications I-Premise
had I-Premise
lower I-Premise
MSTS I-Premise
and I-Premise
TESS I-Premise
scores I-Premise
in I-Premise
the I-Premise
first I-Premise
2 I-Premise
years I-Premise
after I-Premise
treatment I-Premise
. I-Premise

A O
total O
of O
749 O
patients O
were O
randomized O
and O
697 O
were O
available O
for O
analysis O
. O

Many B-Premise
patients I-Premise
( I-Premise
24 I-Premise
% I-Premise
) I-Premise
failed I-Premise
to I-Premise
complete I-Premise
at I-Premise
least I-Premise
6 I-Premise
weeks I-Premise
of I-Premise
therapy I-Premise
, I-Premise
including I-Premise
five I-Premise
( I-Premise
8 I-Premise
% I-Premise
) I-Premise
treatment I-Premise
- I-Premise
related I-Premise
early I-Premise
deaths I-Premise
. I-Premise

Pamidronate B-Claim
treatment I-Claim
of I-Claim
breast I-Claim
cancer I-Claim
patients I-Claim
efficaciously I-Claim
reduced I-Claim
skeletal I-Claim
morbidity I-Claim
. I-Claim

We O
performed O
a O
prospective O
randomized O
phase O
III O
study O
to O
examine O
whether O
sequential O
administration O
of O
topotecan O
can O
improve O
the O
efficacy O
of O
carboplatin O
and O
paclitaxel O
in O
first O
- O
line O
treatment O
of O
advanced O
epithelial O
ovarian O
cancer O
. O

Patients O
completed O
a O
comprehensive O
battery O
of O
QOL O
questionnaires O
at O
random O
assignment O
to O
treatment O
and O
at O
1 O
, O
3 O
, O
and O
6 O
months O
later O
. O

Trials B-Claim
with I-Claim
late I-Claim
intensification I-Claim
HDCT I-Claim
have I-Claim
failed I-Claim
to I-Claim
show I-Claim
an I-Claim
advantage I-Claim
in I-Claim
overall I-Claim
survival I-Claim
. I-Claim

The O
laser O
group O
received O
LLLT O
( O
Technomed O
Electronics O
Advanced O
Laser O
Therapy O
1000 O
, O
He O
- O
Ne O
, O
λ O
= O
632 O
. O
8 O
nm O
, O
power O
density O
= O
24 O
mW O
\/ O
cm O
( O
2 O
) O
, O
dosage O
= O
3 O
. O
0 O
J O
at O
each O
point O
, O
total O
dose O
\/ O
session O
= O
36 O
- O
40 O
J O
, O
spot O
size O
1 O
cm O
( O
2 O
) O
, O
irradiation O
time O
\/ O
point O
125 O
s O
) O
before O
each O
radiation O
session O
, O
while O
the O
placebo O
group O
did O
not O
receive O
laser O
therapy O
. O

BMD O
of O
48 O
patients O
were O
analyzed O
"""" O
; O
"""" O
23 O
belongs O
to O
group O
A O
, O
10 O
to O
group O
B O
and O
15 O
to O
group O
C O
. O
The O
serum O
bone O
turnover O
proteins O
bone O
- O
specific O
alkaline O
phosphatase O
( O
BAP O
) O
and O
carboxyterminal O
crosslinked O
telopeptide O
of O
type O
I O
collagen O
( O
ICTP O
) O
, O
were O
measured O
with O
commercially O
available O
test O
kits O
before O
treatment O
, O
3 O
months O
and O
15 O
months O
after O
treatment O
. O

These B-Claim
data I-Claim
suggest I-Claim
the I-Claim
utility I-Claim
of I-Claim
strong I-Claim
opioids I-Claim
for I-Claim
first I-Claim
- I-Claim
line I-Claim
treatment I-Claim
of I-Claim
pain I-Claim
in I-Claim
patients I-Claim
with I-Claim
terminal I-Claim
cancer I-Claim
. I-Claim

Twenty O
- O
eight O
patients O
were O
allocated O
to O
receive O
ATP O
treatment O
and O
30 O
received O
no O
ATP O
. O

A O
phase O
III O
randomized O
trial O
was O
carried O
out O
to O
compare O
two O
schedules O
of O
the O
vinorelbine O
( O
VNR O
) O
- O
cisplatin O
( O
CDDP O
) O
regimen O
in O
patients O
with O
locally O
advanced O
unresectable O
poor O
prognosis O
stage O
IIIB O
or O
metastatic O
stage O
IV O
non O
- O
small O
cell O
lung O
cancer O
. O

Forty O
patients O
on O
Arm O
A O
and O
19 O
on O
Arm O
B O
received O
at O
least O
one O
treatment O
. O

We O
conducted O
a O
randomized O
pilot O
study O
in O
patients O
treated O
with O
four O
fractions O
of O
lung O
SBRT O
delivered O
over O
4 O
or O
over O
11 O
days O
. O

The O
aim O
of O
this O
trial O
was O
to O
determine O
the O
value O
of O
thymidylate O
synthase O
( O
TS O
) O
, O
a O
key O
enzyme O
of O
DNA O
synthesis O
and O
target O
of O
5 O
- O
FU O
, O
to O
predict O
response O
to O
chemotherapy O
of O
mCRC O
. O

Grade B-Premise
3 I-Premise
\/ I-Premise
4 I-Premise
non I-Premise
- I-Premise
hematological I-Premise
toxicity I-Premise
was I-Premise
higher I-Premise
in I-Premise
Arm I-Premise
B I-Premise
( I-Premise
31 I-Premise
% I-Premise
versus I-Premise
22 I-Premise
% I-Premise
P I-Premise
= I-Premise
0 I-Premise
. I-Premise
001 I-Premise
) I-Premise
. I-Premise

Induction B-Premise
chemotherapy I-Premise
was I-Premise
completed I-Premise
in I-Premise
78 I-Premise
% I-Premise
of I-Premise
the I-Premise
patients I-Premise
. I-Premise

The B-Premise
overall I-Premise
response I-Premise
rate I-Premise
was I-Premise
34 I-Premise
. I-Premise
6 I-Premise
% I-Premise
for I-Premise
NP I-Premise
and I-Premise
35 I-Premise
. I-Premise
7 I-Premise
% I-Premise
for I-Premise
NIP I-Premise
. I-Premise

Treatment B-Claim
with I-Claim
PB I-Claim
+ I-Claim
G I-Claim
increased I-Claim
the I-Claim
incidence I-Claim
of I-Claim
severe I-Claim
neutropenia I-Claim
and I-Claim
dyspnea I-Claim
, I-Claim
although B-Claim
the I-Claim
regimen I-Claim
generally I-Claim
was I-Claim
well I-Claim
tolerated I-Claim
. I-Claim

Anxiety B-Premise
was I-Premise
higher I-Premise
in I-Premise
the I-Premise
SPCG I-Premise
- I-Premise
4 I-Premise
groups I-Premise
( I-Premise
77 I-Premise
[ I-Premise
43 I-Premise
% I-Premise
] I-Premise
of I-Premise
178 I-Premise
and I-Premise
69 I-Premise
[ I-Premise
43 I-Premise
% I-Premise
] I-Premise
of I-Premise
161 I-Premise
men I-Premise
) I-Premise
than I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
( I-Premise
68 I-Premise
[ I-Premise
33 I-Premise
% I-Premise
] I-Premise
of I-Premise
208 I-Premise
men I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
relative I-Premise
risk I-Premise
1 I-Premise
· I-Premise
42 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
1 I-Premise
· I-Premise
07 I-Premise
- I-Premise
1 I-Premise
· I-Premise
88 I-Premise
) I-Premise
. I-Premise

Radiother O
Oncol O
104 O
: O
349 O
- O
354 O
, O
2012 O
) O
. O

This O
study O
took O
place O
at O
the O
Royal O
Prince O
Alfred O
Hospital O
, O
Sydney O
, O
Australia O
. O

No B-Premise
significant I-Premise
difference I-Premise
in I-Premise
any I-Premise
of I-Premise
these I-Premise
measures I-Premise
was I-Premise
noted I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
. I-Premise

The O
CCSP O
intervention O
was O
taught O
2 O
week O
before O
hospital O
admission O
with O
reinforcement O
at O
specified O
times O
during O
treatment O
and O
3 O
months O
after O
discharge O
. O

In B-Claim
recurrent I-Claim
low I-Claim
- I-Claim
grade I-Claim
lymphoma I-Claim
, I-Claim
fludarabine I-Claim
improves I-Claim
PFS I-Claim
, I-Claim
TFS I-Claim
, I-Claim
and I-Claim
social I-Claim
function I-Claim
scores I-Claim
in I-Claim
comparison I-Claim
with I-Claim
CVP I-Claim
but I-Claim
does I-Claim
not I-Claim
improve I-Claim
OS I-Claim
. I-Claim

A B-Claim
carboplatin I-Claim
containing I-Claim
regimen I-Claim
with I-Claim
better I-Claim
toxicity I-Claim
profile I-Claim
and I-Claim
a I-Claim
similar I-Claim
potentiality I-Claim
for I-Claim
symptoms I-Claim
control I-Claim
offers I-Claim
an I-Claim
option I-Claim
in I-Claim
comparison I-Claim
to I-Claim
similar I-Claim
cisplatin I-Claim
containing I-Claim
combinations I-Claim
in I-Claim
the I-Claim
palliative I-Claim
treatment I-Claim
of I-Claim
advanced I-Claim
NSCLC I-Claim
. I-Claim

To O
test O
this O
hypothesis O
, O
the O
National O
Surgical O
Adjuvant O
Breast O
and O
Bowel O
Project O
initiated O
the O
Breast O
Cancer O
Prevention O
Trial O
( O
P O
- O
1 O
) O
in O
1992 O
. O

For B-Premise
sexually I-Premise
active I-Premise
female I-Premise
rectal I-Premise
and I-Premise
anal I-Premise
cancer I-Premise
survivors I-Premise
enrolled I-Premise
in I-Premise
a I-Premise
sexual I-Premise
health I-Premise
intervention I-Premise
, I-Premise
sexual I-Premise
dysfunction I-Premise
was I-Premise
significantly I-Premise
and I-Premise
consistently I-Premise
associated I-Premise
with I-Premise
specific I-Premise
measures I-Premise
of I-Premise
psychological I-Premise
well I-Premise
- I-Premise
being I-Premise
, I-Premise
most I-Premise
notably I-Premise
Sexual I-Premise
\/ I-Premise
Relationship I-Premise
Satisfaction I-Premise
. I-Premise

Severe B-Premise
toxicities I-Premise
of I-Premise
TOM I-Premise
+ I-Premise
LFA I-Premise
- I-Premise
5 I-Premise
- I-Premise
FU I-Premise
were I-Premise
neutropenia I-Premise
( I-Premise
16 I-Premise
% I-Premise
) I-Premise
and I-Premise
diarrhoea I-Premise
( I-Premise
16 I-Premise
% I-Premise
) I-Premise
, I-Premise
but I-Premise
median I-Premise
relative I-Premise
DI8 I-Premise
was I-Premise
93 I-Premise
% I-Premise
for I-Premise
TOM I-Premise
, I-Premise
and I-Premise
82 I-Premise
% I-Premise
for I-Premise
5 I-Premise
- I-Premise
FU I-Premise
. I-Premise

Patients O
were O
randomized O
to O
receive O
treatment O
over O
4 O
consecutive O
days O
or O
over O
11 O
days O
. O

Tamoxifen B-Premise
administration I-Premise
did I-Premise
not I-Premise
alter I-Premise
the I-Premise
average I-Premise
annual I-Premise
rate I-Premise
of I-Premise
ischemic I-Premise
heart I-Premise
disease I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
however I-Premise
, I-Premise
a I-Premise
reduction I-Premise
in I-Premise
hip I-Premise
, I-Premise
radius I-Premise
( I-Premise
Colles I-Premise
' I-Premise
) I-Premise
, I-Premise
and I-Premise
spine I-Premise
fractures I-Premise
was I-Premise
observed I-Premise
. I-Premise

The O
effects O
, O
safety O
, O
and O
QoL O
were O
determined O
and O
analyzed O
. O

Stage O
IV O
breast O
cancer O
patients O
were O
randomized O
to O
receive O
either O
160 O
, O
800 O
, O
or O
1 O
, O
600 O
mg O
\/ O
d O
of O
megestrol O
acetate O
. O

Beyond B-Premise
tumor I-Premise
and I-Premise
nodal I-Premise
stage I-Premise
, I-Premise
Karnofsky I-Premise
performance I-Premise
status I-Premise
, I-Premise
primary I-Premise
site I-Premise
, I-Premise
cigarette I-Premise
use I-Premise
, I-Premise
use I-Premise
of I-Premise
concurrent I-Premise
chemotherapy I-Premise
, I-Premise
and I-Premise
altered I-Premise
fractionation I-Premise
schedules I-Premise
, I-Premise
the I-Premise
FACT I-Premise
- I-Premise
H I-Premise
& I-Premise
amp I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
N I-Premise
score I-Premise
was I-Premise
independently I-Premise
predictive I-Premise
of I-Premise
LRC I-Premise
( I-Premise
but I-Premise
not I-Premise
OS I-Premise
) I-Premise
, I-Premise
with I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
0038 I-Premise
. I-Premise

Our O
primary O
end O
point O
was O
patient O
- O
rated O
physical O
functioning O
assessed O
by O
the O
Trial O
Outcome O
Index O
- O
Anemia O
. O

Treatment B-Claim
with I-Claim
radiotherapy I-Claim
and I-Claim
5 I-Claim
- I-Claim
fluorouracil I-Claim
changed I-Claim
only I-Claim
some I-Claim
aspects I-Claim
of I-Claim
quality I-Claim
of I-Claim
life I-Claim
and I-Claim
did I-Claim
not I-Claim
have I-Claim
a I-Claim
significant I-Claim
impact I-Claim
on I-Claim
quality I-Claim
of I-Claim
life I-Claim
. I-Claim

Two O
hundred O
seventy O
one O
patients O
( O
89 O
% O
of O
randomized O
) O
submitted O
the O
baseline O
QOL O
questionnaires O
and O
were O
included O
in O
the O
QOL O
analysis O
. O

Seventy B-Premise
- B-Premise
one B-Premise
percent I-Premise
of I-Premise
patients I-Premise
in I-Premise
the I-Premise
EDS I-Premise
group I-Premise
and I-Premise
76 I-Premise
% I-Premise
in I-Premise
the I-Premise
QW I-Premise
group I-Premise
achieved I-Premise
the I-Premise
target I-Premise
hemoglobin I-Premise
of I-Premise
≥11 I-Premise
. I-Premise
0 I-Premise
g I-Premise
\/ I-Premise
dL I-Premise
. I-Premise

The B-Premise
median I-Premise
OS I-Premise
was I-Premise
24 I-Premise
months I-Premise
for I-Premise
the I-Premise
HDCT I-Premise
arm I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
21 I-Premise
to I-Premise
35 I-Premise
months I-Premise
) I-Premise
and I-Premise
28 I-Premise
months I-Premise
for I-Premise
ST I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
22 I-Premise
to I-Premise
33 I-Premise
months I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
, I-Premise
0 I-Premise
. I-Premise
9 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0 I-Premise
. I-Premise
6 I-Premise
to I-Premise
1 I-Premise
. I-Premise
2 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
P I-Premise
= I-Premise
. I-Premise
43 I-Premise
) I-Premise
. I-Premise

Mean O
scores O
of O
individual O
domains O
\/ O
scales O
of O
3D O
- O
CRT O
and O
IMRT O
were O
compared O
using O
' O
t O
' O
test O
at O
each O
time O
point O
"""" O
; O
"""" O
while O
longitudinal O
change O
in O
mean O
scores O
of O
both O
groups O
over O
time O
was O
evaluated O
by O
repeated O
measurement O
analysis O
of O
variance O
. O

Previously O
untreated O
patients O
with O
SCLC O
with O
extensive O
disease O
or O
limited O
stage O
with O
poor O
prognostic O
factors O
were O
randomly O
assigned O
to O
six O
3 O
- O
weekly O
cycles O
of O
GC O
or O
PE O
. O

These B-Claim
findings I-Claim
demonstrate I-Claim
clinically I-Claim
meaningful I-Claim
, I-Claim
transitory I-Claim
HRQoL I-Claim
decrements I-Claim
with I-Claim
VMP I-Claim
and I-Claim
relatively I-Claim
lower I-Claim
HRQoL I-Claim
vs I-Claim
. I-Claim
MP I-Claim
during I-Claim
early I-Claim
treatment I-Claim
cycles I-Claim
, I-Claim
associated I-Claim
with I-Claim
the I-Claim
expected I-Claim
additional I-Claim
toxicities I-Claim
. I-Claim

37 B-Premise
( I-Premise
11 I-Premise
% I-Premise
) I-Premise
of I-Premise
350 I-Premise
in I-Premise
the I-Premise
combined I-Premise
group I-Premise
and I-Premise
23 I-Premise
( I-Premise
7 I-Premise
% I-Premise
) I-Premise
of I-Premise
35 I-Premise
in I-Premise
the I-Premise
endocrine I-Premise
- I-Premise
only I-Premise
group I-Premise
had I-Premise
overall I-Premise
bother I-Premise
from I-Premise
all I-Premise
bowel I-Premise
symptoms I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
022 I-Premise
) I-Premise
. I-Premise

Although B-Premise
our I-Premise
patient I-Premise
sample I-Premise
was I-Premise
small I-Premise
and I-Premise
patients I-Premise
who I-Premise
did I-Premise
not I-Premise
complete I-Premise
the I-Premise
follow I-Premise
- I-Premise
up I-Premise
survey I-Premise
were I-Premise
present I-Premise
, I-Premise
we B-Claim
could I-Claim
not I-Claim
identify I-Claim
any I-Claim
clinical I-Claim
difference I-Claim
between I-Claim
INT I-Claim
and I-Claim
RY I-Claim
after I-Claim
total I-Claim
gastrectomy I-Claim
60 I-Claim
months I-Claim
after I-Claim
surgery I-Claim
. I-Claim

Patients O
( O
age O
range O
, O
16 O
to O
80 O
years O
) O
had O
tumor O
stage O
T1 O
to O
T3 O
, O
with O
possible O
spread O
to O
nearby O
lymph O
nodes O
but O
without O
metastasis O
. O

Exploratory O
analyses O
were O
performed O
on O
a O
data O
set O
from O
a O
previous O
study O
. O

The O
exercise O
group O
followed O
a O
progressive O
, O
8 O
- O
week O
upper O
- O
body O
exercise O
program O
consisting O
of O
resistance O
training O
plus O
aerobic O
exercise O
using O
a O
Monark O
Rehab O
Trainer O
arm O
ergometer O
. O

In B-Premise
multivariate I-Premise
analysis I-Premise
, I-Premise
prophylactic I-Premise
alpha I-Premise
- I-Premise
blockers I-Premise
resulted I-Premise
in I-Premise
statistically I-Premise
lower I-Premise
maximum I-Premise
dysuria I-Premise
scores I-Premise
, I-Premise
while B-Premise
the I-Premise
maximum I-Premise
IPSS I-Premise
after I-Premise
implantation I-Premise
and I-Premise
isotope I-Premise
type I-Premise
( I-Premise
but I-Premise
only I-Premise
at I-Premise
6 I-Premise
months I-Premise
) I-Premise
were I-Premise
the I-Premise
best I-Premise
predictors I-Premise
of I-Premise
the I-Premise
resolution I-Premise
of I-Premise
dysuria I-Premise
. I-Premise

Follow O
- O
up O
examinations O
were O
performed O
12 O
months O
after O
ablation O
to O
assess O
ablation O
outcome O
in O
each O
group O
by O
131 O
whole O
body O
scans O
( O
WBSs O
) O
, O
serum O
thyroglobulin O
measurement O
after O
TSH O
stimulation O
, O
and O
neck O
ultrasonography O
. O

To O
compare O
the O
effectiveness O
and O
tolerability O
of O
gemcitabine O
plus O
cisplatin O
with O
single O
- O
agent O
gemcitabine O
as O
first O
- O
line O
chemotherapy O
for O
locally O
advanced O
or O
metastatic O
pancreatic O
cancer O
. O

After O
chemotherapy O
those O
in O
the O
treatment O
group O
took O
modified O
FJD O
. O

At B-Premise
20 I-Premise
wk I-Premise
, I-Premise
4 I-Premise
wk I-Premise
after I-Premise
planned I-Premise
interruption I-Premise
of I-Premise
duloxetine I-Premise
, I-Premise
we I-Premise
observed I-Premise
a I-Premise
U I-Premise
- I-Premise
turn I-Premise
, I-Premise
23 I-Premise
patients I-Premise
were I-Premise
completely I-Premise
dry I-Premise
in I-Premise
group I-Premise
A I-Premise
versus I-Premise
38 I-Premise
in I-Premise
group I-Premise
B I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
008 I-Premise
) I-Premise
. I-Premise

A O
total O
of O
421 O
patients O
with O
locally O
advanced O
stage O
III O
or O
stage O
IV O
NSCLC O
tumors O
were O
included O
. O

Treatment B-Premise
arms I-Premise
did I-Premise
not I-Premise
differ I-Premise
regarding I-Premise
withdrawal I-Premise
rate I-Premise
and I-Premise
the I-Premise
experience I-Premise
of I-Premise
( I-Premise
serious I-Premise
) I-Premise
adverse I-Premise
events I-Premise
. I-Premise

Intervention B-Premise
spouses I-Premise
reported I-Premise
higher I-Premise
quality I-Premise
of I-Premise
life I-Premise
, I-Premise
more I-Premise
self I-Premise
- I-Premise
efficacy I-Premise
, I-Premise
better I-Premise
communication I-Premise
, I-Premise
and I-Premise
less I-Premise
negative I-Premise
appraisal I-Premise
of I-Premise
caregiving I-Premise
, I-Premise
uncertainty I-Premise
, I-Premise
hopelessness I-Premise
, I-Premise
and I-Premise
symptom I-Premise
distress I-Premise
at I-Premise
4 I-Premise
months I-Premise
compared I-Premise
with I-Premise
controls I-Premise
, I-Premise
and I-Premise
some I-Premise
effects I-Premise
were I-Premise
sustained I-Premise
to I-Premise
8 I-Premise
months I-Premise
and I-Premise
12 I-Premise
months I-Premise
. I-Premise

Proportions O
of O
patients O
with O
skeletal O
- O
related O
events O
, O
time O
to O
the O
first O
skeletal O
- O
related O
event O
, O
skeletal O
morbidity O
rate O
, O
pain O
and O
analgesic O
scores O
, O
disease O
progression O
, O
and O
safety O
were O
assessed O
. O

In B-Premise
multivariate I-Premise
analysis I-Premise
, I-Premise
baseline I-Premise
neutrophil I-Premise
( I-Premise
P I-Premise
< I-Premise
0 I-Premise
. I-Premise
001 I-Premise
) I-Premise
, I-Premise
baseline I-Premise
platelet I-Premise
counts I-Premise
( I-Premise
P I-Premise
< I-Premise
0 I-Premise
. I-Premise
001 I-Premise
) I-Premise
and I-Premise
the I-Premise
difference I-Premise
between I-Premise
white I-Premise
blood I-Premise
cell I-Premise
( I-Premise
WBC I-Premise
) I-Premise
and I-Premise
neutrophil I-Premise
count I-Premise
( I-Premise
P I-Premise
= I-Premise
0 I-Premise
. I-Premise
009 I-Premise
) I-Premise
had I-Premise
a I-Premise
significant I-Premise
adverse I-Premise
prognostic I-Premise
value I-Premise
. I-Premise

Long B-Premise
- B-Premise
term B-Premise
benefits I-Premise
for I-Premise
older I-Premise
patients I-Premise
were I-Premise
seen I-Premise
in I-Premise
the I-Premise
anger I-Premise
- I-Premise
hostility I-Premise
scale I-Premise
at I-Premise
week I-Premise
27 I-Premise
( I-Premise
92 I-Premise
. I-Premise
2 I-Premise
vs I-Premise
. I-Premise
84 I-Premise
. I-Premise
2 I-Premise
, I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
027 I-Premise
) I-Premise
and I-Premise
week I-Premise
52 I-Premise
( I-Premise
96 I-Premise
. I-Premise
3 I-Premise
vs I-Premise
. I-Premise
85 I-Premise
. I-Premise
9 I-Premise
, I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
005 I-Premise
) I-Premise
. I-Premise

No B-Premise
unique I-Premise
safety I-Premise
observations I-Premise
were I-Premise
reported I-Premise
during I-Premise
open I-Premise
- I-Premise
label I-Premise
exposure I-Premise
. I-Premise

BT O
plans O
were O
revised O
before O
each O
CTX O
and O
30 O
, O
60 O
, O
and O
90 O
days O
after O
the O
last O
CTX O
and O
reinforced O
7 O
to O
9 O
days O
later O
. O

No B-Premise
statistically I-Premise
significant I-Premise
difference I-Premise
was I-Premise
found I-Premise
among I-Premise
the I-Premise
treatment I-Premise
arms I-Premise
. I-Premise

Fatigue O
is O
the O
most O
commonly O
reported O
symptom O
in O
all O
cancer O
patients O
. O

Anemia B-Claim
is I-Claim
an I-Claim
expected I-Claim
consequence I-Claim
of I-Claim
intensive I-Claim
chemotherapy I-Claim
regimens I-Claim
administered I-Claim
to I-Claim
patients I-Claim
with I-Claim
acute I-Claim
leukemia I-Claim
. I-Claim

We O
randomised O
149 O
patients O
and O
analysed O
74 O
in O
each O
arm O
. O

The B-Claim
study I-Claim
fails I-Claim
to I-Claim
demonstrate I-Claim
efficacy I-Claim
of I-Claim
dl I-Claim
- I-Claim
alpha I-Claim
tocopheryl I-Claim
acetate I-Claim
plus I-Claim
pentoxifylline I-Claim
in I-Claim
patients I-Claim
with I-Claim
arm I-Claim
lymphoedema I-Claim
following I-Claim
axillary I-Claim
surgery I-Claim
and I-Claim
lymphatic I-Claim
radiotherapy I-Claim
, I-Claim
nor I-Claim
does I-Claim
it I-Claim
suggest I-Claim
any I-Claim
benefits I-Claim
of I-Claim
these I-Claim
drugs I-Claim
in I-Claim
radiation I-Claim
- I-Claim
induced I-Claim
induration I-Claim
( I-Claim
fibrosis I-Claim
) I-Claim
in I-Claim
the I-Claim
breast I-Claim
, I-Claim
chest I-Claim
wall I-Claim
, I-Claim
pectoral I-Claim
fold I-Claim
, I-Claim
axilla I-Claim
or I-Claim
supraclavicular I-Claim
fossa I-Claim
. I-Claim

Quality B-Premise
of I-Premise
life I-Premise
( I-Premise
QOL I-Premise
) I-Premise
declined I-Premise
significantly I-Premise
over I-Premise
the I-Premise
6 I-Premise
months I-Premise
. I-Premise

The B-Claim
safer I-Claim
and I-Claim
simpler I-Claim
RY I-Claim
method I-Claim
may I-Claim
be I-Claim
a I-Claim
more I-Claim
suitable I-Claim
reconstruction I-Claim
method I-Claim
than I-Claim
INT I-Claim
after I-Claim
total I-Claim
gastrectomy I-Claim
. I-Claim

Vandetanib B-Premise
patients I-Premise
had I-Premise
more I-Premise
toxicity I-Premise
and I-Premise
required I-Premise
more I-Premise
dose I-Premise
modifications I-Premise
for I-Premise
gastrointestinal I-Premise
toxicity I-Premise
and I-Premise
rash I-Premise
. I-Premise

The B-Claim
superiority I-Claim
of I-Claim
combination I-Claim
therapy I-Claim
over I-Claim
monochemotherapy I-Claim
has I-Claim
not I-Claim
been I-Claim
demonstrated I-Claim
convincingly I-Claim
. I-Claim

A B-Premise
similar I-Premise
pattern I-Premise
was I-Premise
observed I-Premise
for I-Premise
knee I-Premise
extensor I-Premise
muscles I-Premise
( I-Premise
P I-Premise
= I-Premise
. I-Premise
02 I-Premise
) I-Premise
. I-Premise

Fatigue B-Premise
was I-Premise
lower I-Premise
at I-Premise
1 I-Premise
year I-Premise
than I-Premise
before I-Premise
CTX I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
no B-Premise
group I-Premise
effects I-Premise
were I-Premise
found I-Premise
. I-Premise

During B-Premise
treatment I-Premise
, I-Premise
quality I-Premise
of I-Premise
life I-Premise
declined I-Premise
significantly I-Premise
more I-Premise
with I-Premise
the I-Premise
16 I-Premise
- I-Premise
week I-Premise
regimen I-Premise
than I-Premise
CAF I-Premise
, I-Premise
but B-Premise
by I-Premise
4 I-Premise
months I-Premise
posttreatment I-Premise
, I-Premise
there I-Premise
was I-Premise
no I-Premise
difference I-Premise
. I-Premise

Improvement B-Premise
in I-Premise
physical I-Premise
functioning I-Premise
correlated I-Premise
positively I-Premise
with I-Premise
weight I-Premise
gain I-Premise
( I-Premise
r I-Premise
= I-Premise
0 I-Premise
. I-Premise
56 I-Premise
, I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
001 I-Premise
) I-Premise
. I-Premise

The B-Premise
incremental I-Premise
cost I-Premise
- I-Premise
effectiveness I-Premise
ratio I-Premise
of I-Premise
GJJ I-Premise
compared I-Premise
to I-Premise
stent I-Premise
placement I-Premise
was I-Premise
euro164 I-Premise
per I-Premise
extra I-Premise
day I-Premise
with I-Premise
a I-Premise
gastric I-Premise
outlet I-Premise
obstruction I-Premise
scoring I-Premise
system I-Premise
( I-Premise
GOOSS I-Premise
) I-Premise
> I-Premise
or I-Premise
= I-Premise
2 I-Premise
adjusted I-Premise
for I-Premise
survival I-Premise
. I-Premise

At B-Premise
12 I-Premise
months I-Premise
, I-Premise
63 I-Premise
% I-Premise
of I-Premise
intervention I-Premise
patients I-Premise
had I-Premise
a I-Premise
50 I-Premise
% I-Premise
or I-Premise
greater I-Premise
reduction I-Premise
in I-Premise
depressive I-Premise
symptoms I-Premise
from I-Premise
baseline I-Premise
as I-Premise
assessed I-Premise
by I-Premise
the I-Premise
Patient I-Premise
Health I-Premise
Questionnaire I-Premise
- I-Premise
9 I-Premise
( I-Premise
PHQ I-Premise
- I-Premise
9 I-Premise
) I-Premise
depression I-Premise
scale I-Premise
compared I-Premise
with I-Premise
50 I-Premise
% I-Premise
of I-Premise
EUC I-Premise
patients I-Premise
( I-Premise
odds I-Premise
ratio I-Premise
[ I-Premise
OR I-Premise
] I-Premise
= I-Premise
1 I-Premise
. I-Premise
98 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
1 I-Premise
. I-Premise
16 I-Premise
to I-Premise
3 I-Premise
. I-Premise
38 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
P I-Premise
= I-Premise
. I-Premise
01 I-Premise
) I-Premise
. I-Premise

Only B-Premise
the I-Premise
FACT I-Premise
- I-Premise
G I-Premise
social I-Premise
\/ I-Premise
family I-Premise
well I-Premise
- I-Premise
being I-Premise
subscale I-Premise
had I-Premise
no I-Premise
relationship I-Premise
with I-Premise
EQ I-Premise
- I-Premise
5D I-Premise
responses I-Premise
and I-Premise
utility I-Premise
scores I-Premise
. I-Premise

At B-Premise
four I-Premise
weeks I-Premise
, I-Premise
patients I-Premise
who I-Premise
received I-Premise
thalidomide I-Premise
had I-Premise
gained I-Premise
on I-Premise
average I-Premise
0 I-Premise
. I-Premise
37 I-Premise
kg I-Premise
in I-Premise
weight I-Premise
and I-Premise
1 I-Premise
. I-Premise
0 I-Premise
cm I-Premise
( I-Premise
3 I-Premise
) I-Premise
in I-Premise
arm I-Premise
muscle I-Premise
mass I-Premise
( I-Premise
AMA I-Premise
) I-Premise
compared I-Premise
with I-Premise
a I-Premise
loss I-Premise
of I-Premise
2 I-Premise
. I-Premise
21 I-Premise
kg I-Premise
( I-Premise
absolute I-Premise
difference I-Premise
- I-Premise
2 I-Premise
. I-Premise
59 I-Premise
kg I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
( I-Premise
CI I-Premise
) I-Premise
- I-Premise
4 I-Premise
. I-Premise
3 I-Premise
to I-Premise
- I-Premise
0 I-Premise
. I-Premise
8 I-Premise
) I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
005 I-Premise
) I-Premise
and I-Premise
4 I-Premise
. I-Premise
46 I-Premise
cm I-Premise
( I-Premise
3 I-Premise
) I-Premise
( I-Premise
absolute I-Premise
difference I-Premise
- I-Premise
5 I-Premise
. I-Premise
6 I-Premise
cm I-Premise
( I-Premise
3 I-Premise
) I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
- I-Premise
8 I-Premise
. I-Premise
9 I-Premise
to I-Premise
- I-Premise
2 I-Premise
. I-Premise
2 I-Premise
) I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
002 I-Premise
) I-Premise
in I-Premise
the I-Premise
placebo I-Premise
group I-Premise
. I-Premise

Ablation B-Premise
success I-Premise
rates I-Premise
were I-Premise
85 I-Premise
. I-Premise
0 I-Premise
% I-Premise
in I-Premise
the I-Premise
group I-Premise
receiving I-Premise
low I-Premise
- I-Premise
dose I-Premise
radioiodine I-Premise
versus I-Premise
88 I-Premise
. I-Premise
9 I-Premise
% I-Premise
in I-Premise
the I-Premise
group I-Premise
receiving I-Premise
the I-Premise
high I-Premise
dose I-Premise
and I-Premise
87 I-Premise
. I-Premise
1 I-Premise
% I-Premise
in I-Premise
the I-Premise
thyrotropin I-Premise
alfa I-Premise
group I-Premise
versus I-Premise
86 I-Premise
. I-Premise
7 I-Premise
% I-Premise
in I-Premise
the I-Premise
group I-Premise
undergoing I-Premise
thyroid I-Premise
hormone I-Premise
withdrawal I-Premise
. I-Premise

No B-Premise
differences I-Premise
in I-Premise
QOL I-Premise
between I-Premise
groups I-Premise
2 I-Premise
and I-Premise
3 I-Premise
were I-Premise
found I-Premise
. I-Premise

The B-Premise
incidence I-Premise
and I-Premise
type I-Premise
of I-Premise
adverse I-Premise
events I-Premise
were I-Premise
consistent I-Premise
between I-Premise
the I-Premise
double I-Premise
- I-Premise
blind I-Premise
and I-Premise
cumulative I-Premise
( I-Premise
double I-Premise
- I-Premise
blind I-Premise
plus I-Premise
long I-Premise
- I-Premise
term I-Premise
extension I-Premise
) I-Premise
periods I-Premise
. I-Premise

Tamoxifen B-Claim
decreases I-Claim
the I-Claim
incidence I-Claim
of I-Claim
invasive I-Claim
and I-Claim
noninvasive I-Claim
breast I-Claim
cancer I-Claim
. I-Claim

Mean B-Premise
change I-Premise
in I-Premise
EXIT25 I-Premise
scores I-Premise
from I-Premise
baseline I-Premise
to I-Premise
cycle I-Premise
4 I-Premise
in I-Premise
the I-Premise
epoetin I-Premise
alfa I-Premise
group I-Premise
was I-Premise
1 I-Premise
. I-Premise
3 I-Premise
+ I-Premise
\/ I-Premise
- I-Premise
3 I-Premise
. I-Premise
3 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
the B-Premise
mean I-Premise
change I-Premise
was I-Premise
0 I-Premise
. I-Premise
3 I-Premise
+ I-Premise
\/ I-Premise
- I-Premise
2 I-Premise
. I-Premise
4 I-Premise
in I-Premise
the I-Premise
placebo I-Premise
group I-Premise
( I-Premise
a I-Premise
negative I-Premise
change I-Premise
indicates I-Premise
improved I-Premise
executive I-Premise
function I-Premise
) I-Premise
. I-Premise

However B-Premise
, I-Premise
a I-Premise
trend I-Premise
for I-Premise
more I-Premise
favorable I-Premise
overall I-Premise
survival I-Premise
was I-Premise
documented I-Premise
in I-Premise
the I-Premise
PLD I-Premise
arm I-Premise
compared I-Premise
with I-Premise
the I-Premise
GEM I-Premise
arm I-Premise
, I-Premise
although B-Premise
the I-Premise
P I-Premise
value I-Premise
was I-Premise
of I-Premise
borderline I-Premise
statistical I-Premise
significance I-Premise
( I-Premise
P I-Premise
= I-Premise
. I-Premise
048 I-Premise
) I-Premise
. I-Premise

Median B-Premise
overall I-Premise
survival I-Premise
times I-Premise
were I-Premise
8 I-Premise
. I-Premise
3 I-Premise
, I-Premise
11 I-Premise
. I-Premise
0 I-Premise
, I-Premise
and I-Premise
10 I-Premise
. I-Premise
4 I-Premise
months I-Premise
for I-Premise
ECF I-Premise
, I-Premise
TC I-Premise
, I-Premise
and I-Premise
TCF I-Premise
, I-Premise
respectively I-Premise
. I-Premise

The B-Claim
high I-Claim
effectiveness I-Claim
observed I-Claim
could I-Claim
be I-Claim
attributed I-Claim
in I-Claim
part I-Claim
to I-Claim
early I-Claim
treatment I-Claim
with I-Claim
epoetin I-Claim
alfa I-Claim
. I-Claim

Patients B-Premise
in I-Premise
the I-Premise
78 I-Premise
- I-Premise
Gy I-Premise
arm I-Premise
reported I-Premise
more I-Premise
frequent I-Premise
bowel I-Premise
movements I-Premise
at I-Premise
3 I-Premise
years I-Premise
and I-Premise
less I-Premise
change I-Premise
in I-Premise
bowel I-Premise
function I-Premise
at I-Premise
2 I-Premise
years I-Premise
than I-Premise
patients I-Premise
in I-Premise
the I-Premise
70 I-Premise
- I-Premise
Gy I-Premise
arm I-Premise
. I-Premise

Small B-Claim
sample I-Claim
size I-Claim
precludes I-Claim
definitive I-Claim
answers I-Claim
, I-Claim
but B-Claim
results I-Claim
from I-Claim
this I-Claim
preliminary I-Claim
trial I-Claim
suggest I-Claim
that I-Claim
homeopathy I-Claim
may I-Claim
be I-Claim
of I-Claim
value I-Claim
in I-Claim
the I-Claim
treatment I-Claim
of I-Claim
menopausal I-Claim
symptoms I-Claim
and I-Claim
improving I-Claim
quality I-Claim
of I-Claim
life I-Claim
, I-Claim
especially I-Claim
in I-Claim
those I-Claim
women I-Claim
not I-Claim
on I-Claim
tamoxifen I-Claim
. I-Claim

CBT B-Claim
and I-Claim
PE I-Claim
can I-Claim
have I-Claim
salutary I-Claim
effects I-Claim
on I-Claim
endocrine I-Claim
symptoms I-Claim
and I-Claim
, I-Claim
to I-Claim
a I-Claim
lesser I-Claim
degree I-Claim
, I-Claim
on I-Claim
sexuality I-Claim
and I-Claim
physical I-Claim
functioning I-Claim
of I-Claim
patients I-Claim
with I-Claim
breast I-Claim
cancer I-Claim
experiencing I-Claim
treatment I-Claim
- I-Claim
induced I-Claim
menopause I-Claim
. I-Claim

rhTSH B-Claim
- B-Claim
prepared B-Claim
patients I-Claim
maintained I-Claim
a I-Claim
higher I-Claim
quality I-Claim
of I-Claim
life I-Claim
and I-Claim
received I-Claim
less I-Claim
radiation I-Claim
exposure I-Claim
to I-Claim
the I-Claim
blood I-Claim
. I-Claim

Clinical B-Claim
interventions I-Claim
to I-Claim
address I-Claim
common I-Claim
symptoms I-Claim
associated I-Claim
with I-Claim
treatment I-Claim
should I-Claim
be I-Claim
considered I-Claim
to I-Claim
improve I-Claim
physical I-Claim
and I-Claim
emotional I-Claim
functioning I-Claim
at I-Claim
the I-Claim
end I-Claim
of I-Claim
primary I-Claim
treatment I-Claim
for I-Claim
breast I-Claim
cancer I-Claim
. I-Claim

Exercise B-Claim
training I-Claim
to I-Claim
improve I-Claim
cardiovascular I-Claim
fitness I-Claim
should I-Claim
be I-Claim
considered I-Claim
in I-Claim
the I-Claim
management I-Claim
of I-Claim
lymphoma I-Claim
patients I-Claim
. I-Claim

Postoperative B-Claim
outcomes I-Claim
of I-Claim
patients I-Claim
undergoing I-Claim
laparoscopic I-Claim
- I-Claim
assisted I-Claim
colectomy I-Claim
( I-Claim
LAC I-Claim
) I-Claim
have I-Claim
shown I-Claim
modest I-Claim
improvements I-Claim
in I-Claim
recovery I-Claim
but I-Claim
only I-Claim
minimal I-Claim
differences I-Claim
in I-Claim
quality I-Claim
of I-Claim
life I-Claim
( I-Claim
QOL I-Claim
) I-Claim
compared I-Claim
with I-Claim
open I-Claim
colectomy I-Claim
. I-Claim

No B-Claim
significant I-Claim
differences I-Claim
in I-Claim
terms I-Claim
of I-Claim
response I-Claim
rate I-Claim
, I-Claim
time I-Claim
to I-Claim
progression I-Claim
and I-Claim
overall I-Claim
survival I-Claim
were I-Claim
observed I-Claim
between I-Claim
the I-Claim
two I-Claim
regimen I-Claim
. I-Claim

Compared B-Claim
with I-Claim
IFN5 I-Claim
, I-Claim
IFN1 I-Claim
is I-Claim
neither I-Claim
more I-Claim
nor I-Claim
less I-Claim
effective I-Claim
but I-Claim
is I-Claim
less I-Claim
toxic I-Claim
, I-Claim
with I-Claim
a I-Claim
better I-Claim
reported I-Claim
QOL I-Claim
. I-Claim

Adverse B-Claim
events I-Claim
during I-Claim
temozolomide I-Claim
treatment I-Claim
included I-Claim
thrombocytopenia I-Claim
, I-Claim
nausea I-Claim
, I-Claim
vomiting I-Claim
, I-Claim
anorexia I-Claim
, I-Claim
constipation I-Claim
, I-Claim
alopecia I-Claim
, I-Claim
headache I-Claim
, I-Claim
fatigue I-Claim
, I-Claim
and I-Claim
convulsions I-Claim
. I-Claim

Quality B-Claim
of I-Claim
life I-Claim
during I-Claim
maintenance I-Claim
therapy I-Claim
with I-Claim
pemetrexed I-Claim
is I-Claim
similar I-Claim
to I-Claim
placebo I-Claim
, I-Claim
except B-Claim
for I-Claim
a I-Claim
small I-Claim
increase I-Claim
in I-Claim
loss I-Claim
of I-Claim
appetite I-Claim
, I-Claim
and I-Claim
significantly I-Claim
delayed I-Claim
worsening I-Claim
of I-Claim
pain I-Claim
and I-Claim
haemoptysis I-Claim
. I-Claim

With B-Claim
the I-Claim
exception I-Claim
of I-Claim
tumor I-Claim
hemorrhage I-Claim
- I-Claim
type I-Claim
events I-Claim
with I-Claim
gefitinib I-Claim
, I-Claim
the I-Claim
adverse I-Claim
event I-Claim
profiles I-Claim
were I-Claim
generally I-Claim
consistent I-Claim
with I-Claim
those I-Claim
previously I-Claim
observed I-Claim
. I-Claim

There B-Claim
is I-Claim
substantial I-Claim
deterioration I-Claim
in I-Claim
QOL I-Claim
after I-Claim
curative I-Claim
- I-Claim
intent I-Claim
head I-Claim
- I-Claim
neck I-Claim
irradiation I-Claim
that I-Claim
gradually I-Claim
improves I-Claim
over I-Claim
time I-Claim
. I-Claim

At B-Claim
higher I-Claim
doses I-Claim
, I-Claim
however I-Claim
, I-Claim
TMX I-Claim
inhibits I-Claim
HCC I-Claim
through I-Claim
ER I-Claim
- I-Claim
independent I-Claim
mechanisms I-Claim
. I-Claim

Vaginal B-Claim
brachytherapy I-Claim
provides I-Claim
a I-Claim
better I-Claim
QOL I-Claim
, I-Claim
and I-Claim
should I-Claim
be I-Claim
the I-Claim
preferred I-Claim
treatment I-Claim
from I-Claim
a I-Claim
QOL I-Claim
perspective I-Claim
. I-Claim

The B-Claim
efficacy I-Claim
and I-Claim
safety I-Claim
of I-Claim
uterine I-Claim
- I-Claim
artery I-Claim
embolization I-Claim
, I-Claim
as I-Claim
compared I-Claim
with I-Claim
standard I-Claim
surgical I-Claim
methods I-Claim
, I-Claim
for I-Claim
the I-Claim
treatment I-Claim
of I-Claim
symptomatic I-Claim
uterine I-Claim
fibroids I-Claim
remain I-Claim
uncertain I-Claim
. I-Claim

Combined B-Claim
cardiorespiratory I-Claim
and I-Claim
resistance I-Claim
training I-Claim
, I-Claim
even I-Claim
of I-Claim
very I-Claim
brief I-Claim
duration I-Claim
, I-Claim
improves I-Claim
the I-Claim
QOL I-Claim
and I-Claim
the I-Claim
overall I-Claim
physical I-Claim
fitness I-Claim
of I-Claim
women I-Claim
breast I-Claim
cancer I-Claim
survivors I-Claim
. I-Claim

Larger B-Claim
studies I-Claim
should I-Claim
be I-Claim
carried I-Claim
out I-Claim
that I-Claim
also I-Claim
include I-Claim
healthy I-Claim
women I-Claim
who I-Claim
want I-Claim
to I-Claim
avoid I-Claim
hormone I-Claim
replacement I-Claim
therapy I-Claim
. I-Claim

Darbepoetin B-Claim
alfa I-Claim
, I-Claim
when I-Claim
administered I-Claim
synchronously I-Claim
with I-Claim
chemotherapy I-Claim
, I-Claim
on I-Claim
an I-Claim
EDS I-Claim
appears I-Claim
to I-Claim
be I-Claim
similarly I-Claim
efficacious I-Claim
to I-Claim
darbepoetin I-Claim
alfa I-Claim
weekly I-Claim
dosing I-Claim
with I-Claim
no I-Claim
unexpected I-Claim
adverse I-Claim
events I-Claim
. I-Claim

AET B-Claim
significantly I-Claim
improved I-Claim
important I-Claim
patient I-Claim
- I-Claim
rated I-Claim
outcomes I-Claim
and I-Claim
objective I-Claim
physical I-Claim
functioning I-Claim
in I-Claim
lymphoma I-Claim
patients I-Claim
without I-Claim
interfering I-Claim
with I-Claim
medical I-Claim
treatments I-Claim
or I-Claim
response I-Claim
. I-Claim

Doses B-Claim
to I-Claim
the I-Claim
IUS I-Claim
and I-Claim
EUS I-Claim
on I-Claim
MRI I-Claim
\/ I-Claim
CT I-Claim
predicted I-Claim
worse I-Claim
urinary I-Claim
function I-Claim
, I-Claim
with I-Claim
greater I-Claim
bother I-Claim
, I-Claim
irritative I-Claim
symptoms I-Claim
, I-Claim
and I-Claim
urgency I-Claim
. I-Claim

An B-Claim
unplanned I-Claim
safety I-Claim
analysis I-Claim
suggested I-Claim
decreased I-Claim
overall I-Claim
survival I-Claim
in I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
NSCLC I-Claim
treated I-Claim
with I-Claim
epoetin I-Claim
alfa I-Claim
. I-Claim

Patients B-Claim
treated I-Claim
with I-Claim
longer I-Claim
duration I-Claim
therapy I-Claim
( I-Claim
AC→T I-Claim
) I-Claim
had I-Claim
greater I-Claim
symptom I-Claim
severity I-Claim
and I-Claim
poorer I-Claim
QOL I-Claim
at I-Claim
6 I-Claim
months I-Claim
, I-Claim
but I-Claim
did I-Claim
not I-Claim
differ I-Claim
from I-Claim
shorter I-Claim
duration I-Claim
treatments I-Claim
at I-Claim
12 I-Claim
months I-Claim
. I-Claim

Oral B-Claim
Etoposide I-Claim
therapy I-Claim
resulted I-Claim
in I-Claim
better I-Claim
total I-Claim
FLI I-Claim
- I-Claim
C I-Claim
QOL I-Claim
score I-Claim
than I-Claim
radiotherapy I-Claim
. I-Claim

A B-Claim
peer I-Claim
- I-Claim
modeling I-Claim
videotape I-Claim
can I-Claim
accelerate I-Claim
the I-Claim
recovery I-Claim
of I-Claim
energy I-Claim
during I-Claim
the I-Claim
re I-Claim
- I-Claim
entry I-Claim
phase I-Claim
in I-Claim
women I-Claim
treated I-Claim
for I-Claim
breast I-Claim
cancer I-Claim
, I-Claim
particularly I-Claim
among I-Claim
those I-Claim
who I-Claim
feel I-Claim
less I-Claim
prepared I-Claim
for I-Claim
re I-Claim
- I-Claim
entry I-Claim
. I-Claim

GPX1 B-Claim
may I-Claim
be I-Claim
an I-Claim
inherited I-Claim
factor I-Claim
in I-Claim
predicting I-Claim
patients I-Claim
' I-Claim
QOL I-Claim
. I-Claim

Two B-Claim
months I-Claim
after I-Claim
starting I-Claim
treatment I-Claim
there I-Claim
were I-Claim
no I-Claim
significant I-Claim
differences I-Claim
in I-Claim
quality I-Claim
of I-Claim
life I-Claim
between I-Claim
the I-Claim
arms I-Claim
. I-Claim

Efficacy B-Claim
is I-Claim
low I-Claim
but I-Claim
similar I-Claim
to I-Claim
that I-Claim
of I-Claim
other I-Claim
treatments I-Claim
used I-Claim
in I-Claim
this I-Claim
setting I-Claim
. I-Claim

